Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VITALITY BIOPHARMA, INC.

(VBIO)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vitality Biopharma : Letter from Weinberg and Co., P.A. to the Securities and Exchange Commission (Form 8-K)

06/16/2021 | 04:08pm EDT

Exhibit 16.1

June 16, 2021

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-7561

Dear Sirs/Madams:

We have read Item 4.01 of Vitality Biopharma Inc.'s Form 8-K dated June 16, 2021, and agree with the statements made in Item 4.01(a). We have no basis to agree or disagree with other statements of the registrant contained therein.

Yours truly,

/s/ Weinberg & Company, P.A.

Los Angeles, California

Disclaimer

Vitality Biopharma Inc. published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 20:07:10 UTC.


© Publicnow 2021
All news about VITALITY BIOPHARMA, INC.
06/22VITALITY BIOPHARMA : Letter from Michael Cavanaugh to the Company's Shareholders..
PU
06/22VITALITY BIOPHARMA, INC. : Other Events, Financial Statements and Exhibits (form..
AQ
06/16VITALITY BIOPHARMA : Letter from Weinberg and Co., P.A. to the Securities and Ex..
PU
06/16VITALITY BIOPHARMA, INC. : Changes in Registrant's Certifying Accountant, Financ..
AQ
05/19VITALITY BIOPHARMA : Management's Discussion and Analysis of Financial Condition..
AQ
05/19Vitality Biopharma, Inc. Reports Earnings Results for the Full Year Ended Mar..
CI
05/19Vitality Biopharma, Inc. Auditor Raises 'Going Concern' Doubt
CI
03/12VITALITY BIOPHARMA, INC. : Other Events (form 8-K)
AQ
01/29VITALITY BIOPHARMA : Management's Discussion and Analysis of Financial Condition..
AQ
01/29Vitality Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended..
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -0,88 M - -
Net cash 2021 0,85 M - -
P/E ratio 2021 -10,4x
Yield 2021 -
Capitalization 10,4 M 10,4 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 3
Free-Float 67,0%
Chart VITALITY BIOPHARMA, INC.
Duration : Period :
Vitality Biopharma, Inc. Technical Analysis Chart | VBIO | US92849B1070 | MarketScreener
Income Statement Evolution
Managers and Directors
Michael Cavanaugh Chief Executive Officer & Director
Richard McKilligan Controller, Chief Financial & Accounting Officer
Edward F. Feighan Executive Chairman
Brandon Zipp Chief Science Officer
Richard F. Celeste Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VITALITY BIOPHARMA, INC.241.67%10
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-14.71%52 296